Related Experiment Videos
Platelets from diabetic subjects show diminished sensitivity to prostacyclin
European Journal of Clinical Investigation
|October 1, 1982
Summary
Diabetic patients may have reduced prostacyclin production and less sensitive platelets. This dual effect could contribute to the increased vascular disease risk seen in diabetes.
Area of Science:
- Biochemistry
- Endocrinology
- Vascular Biology
Background:
- Prostacyclin, a metabolite of arachidonic acid, exhibits potent antiplatelet and vasodilator properties.
- Evidence indicates reduced arterial prostacyclin production in diabetes.
- Diabetic vascular complications are a significant concern.
Purpose of the Study:
- To investigate the sensitivity of platelets from diabetic subjects to prostacyclin's antiaggregatory effects in vitro.
- To determine if diabetic platelets exhibit altered responses to prostacyclin.
Main Methods:
- In vitro assessment of platelet aggregation.
- Comparison of prostacyclin sensitivity between diabetic and non-diabetic subjects' platelets.
Main Results:
- Platelets from some diabetic patients demonstrated reduced sensitivity to the antiaggregatory effects of prostacyclin.
- This diminished sensitivity was observed in vitro.
Conclusions:
- Diabetic subjects may experience both decreased prostacyclin production and reduced platelet sensitivity to prostacyclin.
- These combined factors may contribute to the elevated incidence of vascular disease in diabetes.